293例不同直径长支架术后3及6个月的冠脉造影随访

目的 对293例长支架支架术病例进行冠脉造影随访和QCA分析,观察其再狭窄(RS)率和靶血管再次重建率(TvR).方法 本中心1998年以来的1845例PTCA/支架术中,植入支架长度≥120 mm且有术后3和6个月冠脉造影随访的连续性病例计293例(除外急性心肌梗死急诊PTCA病例),平均(65.9±8.2)岁,男性79.2%.据植入支架直径将病人分为4组:A组68例,支架直径≥4.0 mm;B组113例,支架直径≥3.5 mm但＜4.0 mm;C组90例,支架直径≥3.0mm但＜3.5 mm;D组22例,支架直径≥2.5 mm但＜3.0 mm.4组病人的基本情况无显著性差异.QCA定量测定每例病人术前、术后即刻、术后3及6个月随访时的病变或支架的最小管腔直径、病变长度、参考血管直径及支架长度.结果 手术成功率为100%.A、B、C、D四组.术前的病变长度分别为(20.92±10.96)mm、(20.01±10.07)mm、(20.13±11.08)mm及(23.08±6.51)mm(P=NS),植入的支架长度分别为(28.40±5.10)mm、(29.85±8.47)mm、(30.20±7.13)mm及(26.42±4.85)mm(P=NS).造影随访时的RS率,3个月时分别为8.8%、15.0%、33.3%及72.7%(P＜0.001),6个月时分别为17.6%、25.7%、41.1%及72.7%(P＜0.001);TVR率3个月时分别为19.1%、30.1%、54.4%及72.7%(P＜0.001),6个月时分别是30.9%、44.2%、66.7%及81.8%(P＜0.001).结论 对于长病变和弥漫性病变植入长支架,在冠脉病变长度及植入支架长度无显著性差异的情况下,植入越大直径的支架,其RS率及TVR率越低.     

比较血管内超声与冠脉造影指导药物洗脱支架治疗冠心病的Meta分析

目的:系统评价血管内超声(intravascular ultrasound,IVUS)与冠脉造影(coronary angiography,CAG)指导药物洗脱支架(drug-eluting stent,DES)治疗冠心病的临床结局?方法:计算机检索PubMed?Embase?Cochrane Library?Scopus和中国生物医学文献数据库,同时手动检索国内外相关心血管会议记录,收集IVUS与CAG指导DES治疗冠心病的临床研究?检索年限为2016年7月之前?采用STATA 12.0软件进行Meta分析?结果:最终纳入23项符合要求的研究,共包含31 685例患者,其中3 192例来自7项随机对照研究?对此23项研究进行临床事件分析,整体结果表明IVUS指导DES治疗冠心病在死亡[比值比(OR):0.63,95%CI:0.55~0.73,P < 0.001]?心肌梗死(OR:0.69,95%CI:0.58~0.82,P < 0.001)?不良心脏事件(major adverse cardiac events,MACE)(OR:0.75,95%CI:0.69~0.82,P < 0.001)?支架内血栓(OR:0.56,95%CI:0.43~0.73,P < 0.001)?靶血管血运重建(OR:0.79,95%CI:0.68~0.93,P < 0.001)?靶病变血运重建(OR:0.75,95%CI:0.62~0.91,P < 0.001)方面优于CAG指导?结论:与CAG指导治疗冠心病相比,IVUS指导DES治疗冠心病能明显改善患者临床结局,有效减少死亡?心肌梗死?MACE?支架内血栓及再次血运重建?但IVUS指导DES治疗更适用于哪些患者群体及病变类型仍有待更多大型随机对照研究进一步验证?     

Efficacy and safety of FIREHAWK(r) abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort

Background Previous studies indicated that long coronary lesions are one of the key predictors of drug-eluting stent (DES) failure.The purpose of this study was to evaluate the efficacy and the safety ...     

Multi-link Vision and MiniVision stent registry in Asian patients with coronary artery disease: a prospective, multi-center study

Background Recent studies have showed that the fine mesh stents are associated with a significant reduction in both clinical and angiographic re-stenosis of the coronary arteries. To maintain a very satisfactory radio-opacity using the stents, Guidant of the USA has designed a new type of bare metal stents （BMS）-Multi-link （ML） Vision / ML MiniVision stents. The clinical outcomes of Asian patients with coronary artery disease （CAD） after implanting the Multi-link Vision or MiniVision stent were investigated in this study. Methods An observational, prospective, multi-center, non-randomized post marketing registry was conducted to demonstrate the efficacy of the BMS- ML Vision / ML MiniVision stents. The primary end point of the registry was clinical target lesion revascularization （TLR） at a 6-month follow-up. The major secondary end points included the rate of major adverse cardiac events （MACE） and serious adverse events （SAE） in hospital and at 6 months; and the rate of clinical TLR as a function of the type of angina. A total of 429 Asian people with 449 lesions from 14 centers were selected for this study, The average reference diameter of the lesions was （3.0±0.5） mm, and the mean length was （15.7±5.0） mm. Results The successful rate of the procedure was 99.3%. Twenty-five percent of the lesions were treated by direct stenting without pre-dilation. Eighty-six percent of the lesions were implanted with ML Vision stent. After the 6-month follow-up, the rate of clinical TLR was 1.4%. The MACE, SAE and target vessel revascularization （TVR） were 6.8%, 3.5% and 1.4% respectively. Conclusion The current registry showed the excellent 6-month clinical outcomes of ML Vision/ML MiniVision stents in Asian patients with CAD.     

Age-based clinical and angiographic outcomes after sirolimus-eluting stent implantation in patients with coronary artery disease

Background Advanced age independently predicts early and late mortality and major adverse cardiac events （MACE） after percutaneous coronary intervention （PCI）. Randomized clinical trials indicate that siroUmus-eluting stent （SES） implantation reduces target lesion revascularization （TLR）, but there are limited data on the impact of age on outcomes following SES implantation in patients with coronary artery disease （CAD） in real-world practice. Methods A total of 333 CAD patients with 453 lesions were enrolled in this study. Subjects were divided into two groups according to age： a young group （〈65 years old, 244 patients with 369 lesions） and elderly group （≥65 years old, 89 patients with 113 lesions）. Clinical follow-up and quantitative coronary angiography （QCA） were performed seven months after PCh Results Baseline clinical, demographic, angiographic, and procedural chararcteristics were similar in both groups, except that there were more female patients in the elderly group （21.3% vs 9.8%, P=-0.006）. Primary success rate was similar in both groups （96.5% in young group vs 95.7% in elderly group, P〉0.05）. During angiographic follow-up at 7 months, binary in-stent restenosis and in-segment restenosis rates were not significantly different between the two groups （4.7% vs 1.8%; 9.7% vs 8.8%, P〉0.05 respectively）. Both sub-acute and late thrombosis rates were similar in the two groups （0.3% vs 0.9% and 1.2% vs 0.9%, P〉0.05 respectively. TLFI was not significantly different between the two groups （6.5% vs 3.5%;P=-0.246）. The rates of bleeding, stroke, angina rehospitalization during the, follow-up period were also similar in both groups （P〉0.05 respectively）. Conclusion Despite a high-risk clinical profile, coronary SES implantation can be safely and effectively performed in elderly patients with a similar procedural success rate, a low complication rate, and excellent 7-month outcomes.     

老年冠心病患者临床特征及PCI术后远期疗效观察

目的 评价老年冠心病患者临床特征及经皮冠状动脉介入术（percutaneous coronary intervention,PCI）后远期安全性及有效性。方法 随机选取2007年1月-2009年1月在解放军总医院心血管内科行冠状动脉支架置入患者632例,将患者分为老年组（≥65岁）和非老年组（〈65岁）,于2012年3月采用电话随访、门诊检查、冠脉造影等随访方式观察患者冠状动脉支架置入后远期不良心血管事件（major adverse cardiac events,MACE）发生情况。结果 老年组与非老年组在女性（24.5%vs 16.8%,P=0.02）、高血压（72.4%vs 59.5%,P=0.001）、吸烟（27.2%vs 53.6%,P=0.001）比例上的差异有统计学意义;PCI术前冠脉造影特征老年组三支病变比例高（44.4%vs 37.3%,P=0.08）;两组MACE发生率差异无统计学意义（12.8%vs 9.1%,P=0.15）,其他不良事件全因死亡率差异有统计学意义（5.5%vs 1.3%,P=0.004）;冠脉造影三支病变中,老年组与非老年组MACE发生率差异无统计学意义（14%vs 8.6%,P=0.23）。结论 老年冠心病患者应当积极控制血压,加强老年女性患者冠心病的筛查。老年冠心病患者冠状动脉支架置入术后远期是安全、有效的。     

Drug-eluting stents improve clinical outcomes in Chinese diabetic patients with de novo coronary artery disease

Diabetes mellitus （DM） has been regarded as an equivalent risk factor as coronary artery disease and is present in nearly 25% of patients who receive percutaneous coronary intervention （PCI）. DM is shown as an adverse predictor for major adverse cardiac events （MACE） after PCI in bare metal stent （BMS） era. Recently, clinical trials have demonstrated the favorable tendency of using drug-eluting stents （DES） in treating diabetic patients with coronary artery disease. This study compared the clinical outcomes between the diabetic patients receiving DES with those receiving BMS in China.     

中青年冠心病患者冠脉造影结果分析

目的：探讨中青年冠心病（CHD）患者冠状动脉造影（CAG）特点。方法：选年龄≤45岁的59例CHD患者，分为不稳定心绞痛（21例）和心肌梗死（38例）两组，分析并对比其冠脉病变的范围和程度，分析心肌梗死的临床与冠脉病变的对应关系。结果：冠脉损伤以左前降支单支病变最多占66.7％，冠脉重度狭窄者多占76.3％，但两组间比较无显著差异；有7例CAG未见异常占11.9％，2例系变异型心绞痛，5例系急性心肌梗死；仅有7例存在侧支循环。结论：中青年CHD患者冠脉病变以左前降支单支受累为主，狭窄程度重，部分患者CAG正常。     

Incidence of thrombosis after implantation of drug-eluting stents in patients with coronary artery disease

Background Randomized clinical trials have demonstrated equivalent safety to bare-metal stents after drug-eluting stents （DES） implantation. However, the DES thrombosis in randomized trials could not be comparable to those observed in clinical practice, frequently including off-label indications. This study sought to assess the incidence of DES thrombosis after implantation of DES in patients with real world coronary artery disease （CAD） in China.
Methods From December 2001 to April 2007, 8190 consecutive patients received the treatment with DES, 5412 patients completed one year follow-up： 2210 with sirolimus-eluting stent Cypher, 1238 with paclitaxel-eluting stent Taxus and 1964 with Chinese sirolimus-eluting stent Firebird, After two years of follow-up, there were 2176 patients （1245 Cypher, 558 Taxus and 373 Firebird）. All patients were treated with aspirin and clopidogrel over at least 9 months.
Results Among 8190 patients, 17 patients had acute stent thrombosis （0.24%）： 7 in the Cypher group, 4 Taxus and 6 Firebird; 23 patients had subacute stent thrombosis： 8 Cypher, 6 Taxus and 9 Firebird. The incidence of acute and subacute thrombosis was 0.49%： 0.50% Cypher, 0.63% Taxus and 0.41% Firebird. The incidence of late thrombosis at one year followup was 0.63%： 0.63% Cypher, 0.88% Taxus and 0.46% Firebird; at two year follow-up the incidence was 0.74%： 0.72% Cypher, 0.90% Taxus and 0.54% Firebird. There was no significant difference among three groups at 1 year and 2 years follow-up.
Conclusion The first generation DES in the treatment of complex lesions are safe and effective if patients are aggressively treated with dual antiplatelet agents.     

糖尿病患者冠心病冠脉造影特点

目的探讨糖尿病合并冠心病患者冠状动脉造影的特点.方法对103例糖尿病合并冠心病患者进行冠脉造影,并与非糖尿病患者比较,同时研究糖尿病合并冠心病的影响因素.结果糖尿病合并冠心病患者的冠脉造影主要表现为1支病变和2支病变;糖尿病组冠状血管的狭窄程度明显高于非糖尿病组,糖尿病程,血糖水平和血脂水平严重影响冠心病的严重程度.结论冠状动脉造影是研究糖尿病合并冠心病的良好方法,糖尿病患者冠心病冠脉造影主要表现为冠状血管病变广泛、严重.     

原发性高血压合并冠心病的临床及冠脉造影分析

目的探讨原发性高血压合并冠心病病人的临床及冠脉造影特点. 方法选择确诊冠心病的住院病人272例,按有无合并高血压分为两组,比较两组的临床及冠脉造影情况.结果①高血压合并冠心病病人年龄偏大、女性所占比率较高、血脂异常及糖尿病发生率较高;②高血压合并冠心病病人的冠脉病变与不合并高血压的冠心病病人相比,多支病变发生率高;③多因素分析结果显示冠脉病变支数与脉压、糖尿病病程相关. 结论高血压合并冠心病病人冠脉病变较重,多支病变发生率高.     

Soluble CD40 ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome

Background Recently,studies have disclosed soluble CD40 ligand （sCD40L） during atherosclerosis development and plaque destabilization.The objective of the present study was to test the hypothesis that sCD40L levels are higher in acute coronary syndrome （ACS） patients with a greater extent of angiographic coronary involvement.Methods This cross-sectional study examined ACS patients who underwent coronary angiography by measuring their sCD40L levels.In order to estimate the serum levels of sCD40L,10 ml of peripheral venous blood was drawn within 24 hours of admission.sCD40L levels were measured using an enzyme-linked immunosorbent assay （ELISA,RapidBio,West Hills,CA,USA）.Demographic data,presence of concomitant diseases,ACS characteristics,and angiographic findings were evaluated.A review of medical records and patient interviews were conducted to assess coronary risk factors.And the severity of coronary artery disease was evaluated using the Gensini score index.Results Two hundred and eighty-nine patients were included in the study,of whom 186 were male,with an average age of 64.1±10.0 years.Median sCD40L levels were 1.7 ng/ml （0.3-7.3 ng/ml） and Gensini scores were 50 （0-228）.After adjusting for demographic variables and cardiovascular risk factors,the Gensini score was associated with the natural logarithm of the sCD40L level （Coefficient b=0.002,95％ CI 0.000-0.003,P=0.029）.Conclusion sCD40L levels were independently associated with angiographic severity of coronary artery disease in patients with ACS.     

Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials

Context  Placement of sirolimus-eluting stents or paclitaxel-eluting stents has emerged as the predominant percutaneous treatment strategy in patients with coronary artery disease (CAD). Whether there are any differences in efficacy and safety between these 2 drug-eluting stents is unclear. Objective  To compare outcomes of sirolimus-eluting and paclitaxel-eluting coronary stents on the basis of data generated by randomized head-to-head clinical trials. Data Sources  PubMed and the Cochrane Central Register of Controlled Trials, conference proceedings from major cardiology meetings, and Internet-based sources of information on clinical trials in cardiology from January 2003 to April 2005. Study Selection  Randomized trials comparing the sirolimus-eluting stent with the paclitaxel-eluting stent in patients with CAD reporting the outcomes of interest (target lesion revascularization, angiographic restenosis, stent thrombosis, myocardial infarction [MI], death, and the composite of death or MI) during a follow-up of at least 6 months. Data Extraction  Two reviewers independently identified studies and abstracted data on sample size, baseline characteristics, and outcomes of interest. Data Synthesis  Six trials, including 3669 patients, met the selection criteria. No significant heterogeneity was found across trials. Target lesion revascularization, the primary outcome of interest, was less frequently performed in patients who were treated with the sirolimus-eluting stent (5.1%) vs the paclitaxel-eluting stent (7.8%) (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.49-0.84; P = .001). Similarly, angiographic restenosis was less frequently observed among patients assigned to the sirolimus-eluting stent (9.3%) vs the paclitaxel-eluting stent (13.1%) (OR, 0.68; 95% CI, 0.55-0.86; P = .001). Event rates for sirolimus-eluting vs paclitaxel-eluting stents were 0.9% and 1.1%, respectively, for stent thrombosis (P = .62); 1.4% and 1.6%, respectively, for death (P = .56); and 4.9% and 5.8%, respectively, for the composite of death or MI (P = .23). Conclusions  Patients receiving sirolimus-eluting stents had a significantly lower risk of restenosis and target vessel revascularization compared with those receiving paclitaxel-eluting stents. Rates of death, death or MI, and stent thrombosis were similar.      

Analysis of coronary artery and clinical feature in patients with coronary heart disease coexisting with non--insulin dependent diabetes mellitus

Thereisapositiverelationshipbetweencoronaryheartdisease(CHD)anddiabetesmellitus(DM),CHDisthemostcommonheartcomplicationofDMandthemainreasontocauseDMpatientstodie.Withthespreadingofcoronaryangiography(CAG)allovertheworld.thecorrectdiagnosisofCHDisincreasing.TherearefewreportsoftheanalyzedcoronaryanglogramandclinicalcharacteristicsofCHDpatientswithDM.CAGprocedurewasperformedearlierinourhospitalandnearly3000casesoftheprocedureshavebeenperformedinourhospitalsince1980s.850casesofthemwered…     

78例冠状动脉病变患者PCI后12个月造影结果分析

目的 评价冠状动脉病变经皮冠状动脉介入(PCI)治疗后中远期支架内狭窄及心功能变化情况.方法 总结2007年1～3月行PCI治疗并于术后12个月行冠脉造影复查的患者78例,对其心绞痛复发率、造影复查再狭窄率和主要不良心脏事件(MACE)的发生率进行回顾分析.结果 78例患者完全性血运重建率100%,术后按冠心病PCI术后治疗指南进行规范药物治疗,住院及随访期间无心源性及非心源性死亡病例,术后12个月造影随访结果 提示6例(7.7%)共16个靶病变(10.6%)发生再狭窄,其中5例共9个靶病变血管需行血运重建治疗.PCI治疗后患者左室射血分数及心功能分级明显改善,心绞痛发作性明显减少.结论 患者PCI术后在规范药物治疗的基础上其再狭窄发生较低,患者中远期随访心功能及心绞痛发生均可明显改善.     

冠心病合并糖尿病患者冠状动脉病变的临床观察

目的：探讨冠状动脉粥样硬化性心脏病（冠心病）合并糖尿病患者的冠状动脉病变特点。方法：回顾分析本院１９９５￣１９９７年冠状动脉造影阳性患者１５３例,分为糖尿病组（３３例）、糖耐量减低组（ＩＧＴ,２３例）和非糖尿病组（９７例）,观察其年龄、冠心病危险因素（包括高血压、高胆固醇血症和吸烟）、心肌梗死发生率和冠状动脉受累情况。结果：３组在年龄、性别、危险因素、 梗死发生率等方面均无显著性差异。糖尿病组冠状     

One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease

The application of drug-eluting stent （DES）, either sirolimus-eluting stent （Cypher, Cordis, USA） or paclitaxel-eluting stent （Taxus, Boston Scientific, USA）, in treatment of patients with coronary artery disease （CAD） has achieved great success. The high cost of imported DES （either Cypher or Taxus） gave the birth to a China-made, polymer-based, sirolimus-eluting stent （Firebird, Microport Company,     

伴有非胰岛素依赖型糖尿病冠心病患者冠状动脉病变和临床 …

目的：探讨伴有非胰岛素依赖型糖尿病（ＮＩＤＤＭ）冠心病患者的冠状动脉病变及其临床特征。方法：用冠脉造影方法分析了８５０例伴有ＮＩＤＤＭ（１５３例）和不伴有ＮＩＤＤＭ（６９７例）冠心病冠脉病变特点并将临床特点加以对照研究。结果：冠心病合并ＮＩＤＤＭ患者伴高血压,脑卒中,高脂血症及阳性家族史率较不伴有ＮＩＤＤＭ冠心病患者明显升高,该组患者无痛型较多,病情重,住院期间病死百分比高,该组合带路屠 易出现中     

国产药物洗脱支架治疗冠心病的造影随访结果

目的通过复查冠脉造影观察国产药物洗脱支架择期治疗冠心病的临床疗效。方法择期接受Firebird支架(雷帕霉素洗脱支架)治疗的57例冠心病患者,78支病变血管的90处罪犯病变置入98枚Firebird支架,随访6~9个月并复查冠脉造影。结果支架内再狭窄率为3.51%。结论国产药物洗脱支架具有良好的临床疗效。